Tag: Contributor Content

A new agreement between Biocon Biologics Ltd. and nonprofit generic drug maker Civica, Inc. is set to expand access to affordable insulin for millions of Americans living with diabetes.

The partnership, announced Wednesday, establishes a distribution deal for a private-label version of Insulin Glargine in the U.S. Under the multi-year partnership, Biocon Biologics will manufacture and supply the long-acting insulin for Civica, which will handle distribution, marketing and commercialization in the U.S. under its own label — and under the CalRx brand in California.

Biocon Biologics will continue its own direct commercialization of Insulin Glargine, complementing the Civica-labeled product to broaden access and give patients multiple ways to obtain affordable insulin.

“Biocon Biologics is committed to expanding access to affordable, high-quality insulins in the U.S. and globally,” said Shreehas Tambe, CEO and managing director of Biocon Biologics, one of the world’s largest producers of insulin, delivering more than 9.2 billion doses globally each year.

“By extending our collaboration with Civica, Inc. to include Insulin Glargine, we are building on our differentiated approach to serving and enhancing patient access—by retaining our direct commercialization and through this strategic partnership,” Tambe said. “This collaboration enables us to reach underserved populations through new channels in direct alignment with our mission.”

The new Insulin Glargine initiative builds upon the existing collaboration between the two companies. In 2025, Biocon Biologics began supplying Civica with Insulin Aspart drug substance for domestic manufacturing as part of a broader effort to address drug affordability.

Civica President and CEO Ned McCoy said the Insulin Glargine expansion brings the company closer to its mission of making essential medicines available at transparent, low prices. “We are pleased to expand our partnership with Biocon Biologics, which helps us achieve a significant milestone in our insulin initiative,” McCoy said. “Today’s announcement allows us to realize our goal of bringing insulin to people who need it at a transparent low price.”

The agreement involves no technology transfer; Biocon Biologics will retain all intellectual property and marketing authorizations for Insulin Glargine. The company’s Insulin Glargine-yfgn medicine, approved by the U.S. Food and Drug Administration in 2021 as the first interchangeable biosimilar, is used to help control blood sugar in adults and children with diabetes.

Scroll to continue reading

Diabetes affects more than 38 million Americans — roughly one in nine — while another 97.6 million are estimated to have prediabetes. Rising drug costs have made insulin a focal point of U.S. health policy debates, with many patients reporting difficulty affording their prescriptions.

Civica plans to distribute its insulin glargine to pharmacies across the United States for $45 for a box of five pens, a significant discount in many cases to current prices. Civica recommends that pharmacies and health plans set a maximum recommended price for consumers of no more than $55.

“California didn’t wait for the pharmaceutical industry to do the right thing — we took matters into our own hands,” said Gov. Gavin Newsom in a statement. “By beginning the process to manufacture our own insulin and pricing it at a maximum cost of $11 a pen in a five-pack, California and Civica are showing the nation what it looks like to put people over profits. No Californian should ever have to ration insulin or go into debt to stay alive.”

McCoy said California shares the company’s vision for increasing access to affordable medicines.

“We are grateful for the support of the state of California for our effort to bring affordable insulin to all Americans,” he said. “The state shares our vision to ensure a sustainable, quality supply of affordable, essential medicines for people who need them.”

This article is intended for informational purposes only and should not be considered medical advice, diagnosis, or treatment. The information provided is based on publicly available details from the featured organizations and does not imply FDA approval or endorsement. Readers should consult a qualified healthcare professional regarding any questions or concerns about medications, treatments, or medical conditions.

Highlights

• Top Los Angeles universities estimate between $1,200–$1,680 for books and materials in 2024–2025.
• One major LA school offers a $129-per-quarter “day-one” digital access program with an opt-out deadline in week 2.
• Studocu helps students learn with shared notes and study tools at a low cost.

Why textbooks in LA are a big deal

What the schools are doing

How students can save with smart choices

How Studocu helps

Studocu is a peer-to-peer study platform with shared notes, summaries, and practice materials from students across more than 120K universities worldwide, including Los Angeles campuses.

• Notes from Real Students: Content created by peers who’ve taken your class.
• Massive Library: Over 50 million documents available.
• AI-Powered Tools: Quick summaries, practice questions, quiz generators, and more.
• Free Premium Access: Upload your notes to unlock Premium or subscribe for just a few dollars a month.
• Trusted by Millions: Over 60 million students each month use Studocu to save money, study faster, and prepare more effectively.

Studocu won’t do your assignments for you, but it will make learning easier, faster, and cheaper.

Keep it fair and honest

Why this matters in LA

Conclusion

Frequently Asked Questions

Los Angeles, the city has been molded by risk and resilience in every decade. Be it earthquakes, fires, droughts, and whatever myriads of disasters that Angelenos prepare against, to them it often comes with a kind of quiet pragmatism. Earthquake kits find their place in closets, stocked bottled water lines, pantry shelves; portable air filters are a common sight during smoky summers. But carbon monoxide continues to go overlooked, despite being just as present in daily life.

Seeping into homes without warning, carbon monoxide is often called the “silent killer.” It can come from gas appliances, fireplaces, or attached garages. In Los Angeles, the danger is magnified by the city’s diverse housing stock. A family living in a 1920s Spanish Revival bungalow in Hancock Park may face risks from aging stoves or furnaces, while a renter in a downtown high-rise might be exposed through poorly ventilated shared systems. Even newly built condos can carry hidden vulnerabilities when appliances aren’t properly maintained.

Though the incident happened in San Bernardino County, the lesson is hard to ignore for Los Angeles residents. California law requires detectors in most residences. Renters may not know if devices are installed or maintained, and in multifamily buildings responsibility can easily slip through the cracks. Even homeowners often let regular testing slide. That uncertainty has led more Angelenos to purchase their own carbon monoxide alarms, portable units they can set up and trust themselves.

One of the devices gaining attention locally is the SITERWELL Plug-In Carbon Monoxide Alarm. Compact enough to fit into the crowded outlet space of a typical LA apartment, it is designed for immediate use — a simple plug-in that activates instantly. Its appeal goes beyond convenience. With a built-in battery backup, the alarm continues to function during outages, a detail that feels especially urgent in a city accustomed to rolling blackouts during wildfire season, when residents are more likely to run gas-powered generators. The design also provides clear, visual reassurance. A green light signals that conditions are normal, while a red light paired with a piercing siren warns when carbon monoxide is detected.

That kind of reassurance is particularly important for families with children or pets. Young children are more vulnerable to carbon monoxide exposure because of their smaller bodies and faster breathing rates, and pet owners know that dogs and cats can suffer the effects even before adults notice symptoms. In neighborhoods across the Valley and Eastside, where multi-generational households are common, portable alarms have become another layer of protection in homes already filled with baby gates, safety locks, and air purifiers.

Yet the growing popularity of these alarms isn’t only about immediate danger. It reflects a broader culture of preparedness that defines life in Los Angeles. Residents are already conditioned to think long-term: they know that an earthquake is not a matter of if but when, and that fire season arrives as predictably as summer. A carbon monoxide alarm, especially one designed to last up to ten years, fits seamlessly into that mindset. It is not just another gadget — it is a habit, a quiet safeguard against risks that can strike without warning.

Scroll to continue reading

Angelenos have always learned to balance the enjoyment of purposes and the idea of the very fragile comforts this environment provides. Putting a carbon monoxide alarm in the home is a slight, almost imperceptible act. But it is another way the city continues to live with its risks while refusing to be defined by them. In a place where uncertainty is part of the landscape, that kind of certainty carries weight.

In Hollywood, production houses tend to follow the script. Chromista insists on writing it. Founded in Los Angeles by Darren Aronofsky, the studio was born from a deceptively radical question: what if commercials weren’t left to marketing executives, but to filmmakers themselves? What if the thirty-second spot could carry the gravity of cinema — not just a slogan, but a story?

The answer has attracted talent that reads more like a film festival lineup than an advertising roster. There’s Eliza McNitt, known for her cosmic VR explorations at Tribeca. Chelsea Odufu, whose Afro-surrealist shorts caught Spike Lee’s attention. Kasra Farahani, who left Marvel’s design departments to build worlds of his own. Andrew DeYoung, the Sundance favorite behind razor-sharp comedies. Elliott Lester, whose HBO dramas have found devoted audiences. Eddie Alcazar, the A24-backed provocateur of hallucinatory cinema.Their collective résumés sparkle with Spirit Awards, Clios, Cannes Lions, and Critics’ Choice nods, while their client work spans from tech giants to luxury brands to conservation nonprofits.

The Anti-Formula Formula

But Aronofsky and his partners aren’t interested in establishing a house style. If anything, their only rule is that there isn’t one. Each project begins not with available directors or trending aesthetics, but with a fundamental question: what story actually needs telling here?

The results often surprise. A director known for slow, grainy 35mm frames might find themselves crafting a Super Bowl spot—and those unexpected, lingering shots amid football’s chaos land with uncommon weight. A fashion label expecting another glossy catalog piece discovers their seasonal collection transformed into kaleidoscopic animation that feels more like a gallery installation. A conservation group pairs with an AI artist to examine technology’s environmental impact, producing work that’s as unsettling as it is memorable.

This willingness to make unexpected pairings sets Chromista apart in an industry often content with recycled visuals and safe choices. Where traditional agencies might assign based on availability or obvious fits, Chromista matches artistic DNA to creative brief—even when that pairing seems counterintuitive at first glance.

Scroll to continue reading

Beyond the Thirty-Second Spot

The studio operates on a simple premise: great storytelling doesn’t stop being great just because it’s serving a brand. Directors aren’t just executing someone else’s vision—they’re finding the deeper narrative that needs to emerge from each brief, then building the creative team around that story.

It’s a process that requires both vision and pragmatism. While the artistic ambition runs high, Chromista’s directors work alongside strategists and production managers who ensure projects deliver on both creative and commercial goals. There’s no room for unchecked artistic ego when deadlines and client objectives are on the line. If the story needs tweaking or the timing requires adjustment, the Chromista team raises those flags early and collaborates until it’s right. The final product matters more than any initial vision—a philosophy that’s produced work where the artistry serves the message rather than overshadowing it.

Culture Over Campaigns

The approach challenges an industry assumption that’s gone largely unquestioned: that advertising creativity is fundamentally different from other forms of filmmaking. By treating each brief as a storytelling opportunity rather than a marketing exercise, Chromista is testing whether the commercial space can produce work that genuinely moves culture forward.

Whether this model represents the future of the industry or remains the vision of one particularly ambitious studio is still unfolding. But in a city built on the mythology of storytelling, there’s something compelling about the idea that even a thirty-second spot might contain more potential than anyone previously imagined.